Research Article

The Safety and Efficiency of Tirofiban in Acute Ischemic Stroke Patients Treated with Mechanical Thrombectomy: A Multicenter Retrospective Cohort Study

Table 1

Demographic and clinical characteristics of the subjects.

CharacteristicTirofiban group N = 89Control group N = 85 value

Sex (male)59 (66.3)43 (50.6)0.036
Age, median (IQR), y68 (56.5–75.0)68 (54.5–77.0)0.640
Smoking25 (28.1)12 (14.1)0.024
Drinking17 (19.1)9 (10.6)0.115
Hypertension50 (56.2)35 (41.2)0.048
T2DM24 (27.0)17 (20.0)0.279
Coronary atherosclerotic disease27 (30.3)26 (30.6)0.971
Atrial fibrillation26 (29.2)51 (60.0)0.000
Previous TIA/stroke17 (19.1)11 (12.9)0.269
NIHSS on admission, median (IQR), point15 (12.0–21.0)16 (13.0–20.0)0.452
ASPECTS/pc-ASPECT, median (IQR), point10 (9.0–10.0)10 (8.3–10.0)0.456
Glucose, median (IQR), mmol/l7.2 (6.2–9.4)7.2 (5.9–9.0)0.457
PLT, median (IQR), ×109/L192 (147.2–236.7)177 (144.0–213.3)0.142
INR, median (IQR), s1.03 (0.95–1.11)1.05 (0.99–1.14)0.064

TOAST
Large artery atherosclerosis68 (76.4)41 (48.2)0.000
Cardioembolism21 (23.6)44 (51.8)0.000

Location of stroke
Anterior circulation stroke69 (77.5)67(78.8)0.836
Posterior circulation stroke20 (22.5)18(21.2)0.836
Median SBP in 24 h, median (IQR), mmHg130 (118.0–145.0)130 (121.3–140.0)0.926
Premorbid antiplatelets17 (19.1)11 (12.9)0.269
Premorbid anticoagulants4 (4.5)11 (12.9)0.047

Data are number, number (%), median (IQR), or mean (SD).